Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 3Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 369Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 140Colorectal Neoplasms 137Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 122Lymphoma 114Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 88Head and Neck Neoplasms 88Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 61Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Rectal Cancer Patients × Clear all
NCT01426074 2018-08-21

DCE-MRI PET Bevacizumab Study in Rectal Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Withdrawn
Gastrointestinal

Rectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡